Literature DB >> 1986621

Venous Doppler ultrasonography in the fetus with nonimmune hydrops.

S Gudmundsson1, J C Huhta, D C Wood, G Tulzer, A W Cohen, S Weiner.   

Abstract

Eighteen pregnancies with nonimmune hydrops fetalis were referred for fetal echocardiography to rule out congenital heart disease. In 14 of these cases, pulsating blood velocities were recorded in the umbilical vein, which in a normal population had a nonpulsatile blood velocity pattern. The four cases without pulsations in the umbilical vein were found to have intrauterine viral infections. In the last 10 cases examined, the umbilical venous pulsations were found to reflect abnormal central venous pulsations during atrial systole suggesting increased fetal central venous pressure. Right ventricular shortening fraction was significantly decreased in the group with umbilical venous pulsations compared with those without (0.18 versus 0.32, p less than 0.05). All the fetuses without venous pulsations survived, but only four of the 14 with pulsations survived (p less than 0.05). The results suggest that blood velocity recordings in the umbilical and central veins of the fetus can give valuable clinical information with regard to the presence of fetal congestive heart failure and differentiate between this physiologic state and other causes of nonimmune hydrops fetalis. This may have implications for fetal diagnostic work-up and prognosis.

Entities:  

Mesh:

Year:  1991        PMID: 1986621     DOI: 10.1016/0002-9378(91)90618-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Mechanical properties of the fetal ductus venosus and umbilical vein.

Authors:  L R Hellevik; T Kiserud; F Irgens; N Stergiopulos; M Hanson
Journal:  Heart Vessels       Date:  1998       Impact factor: 2.037

Review 2.  Fetal cardiovascular physiology.

Authors:  J Rychik
Journal:  Pediatr Cardiol       Date:  2004 May-Jun       Impact factor: 1.655

3.  Fetal left and right ventricle myocardial performance index: defining normal values for the second and third trimesters--single tertiary center experience.

Authors:  Hani Ghawi; Salwa Gendi; Kiran Mallula; Mohammed Zghouzi; Nadeen Faza; Sawsan Awad
Journal:  Pediatr Cardiol       Date:  2013-05-17       Impact factor: 1.655

Review 4.  Morphological and functional evaluation of normal and abnormal fetal growth by ultrasonography.

Authors:  Toshiyuki Yoshizato; Shoji Satoh
Journal:  J Med Ultrason (2001)       Date:  2009-08-12       Impact factor: 1.314

5.  Cardiac function assessment in patients with family history of nonhypertrophic cardiomyopathy: a prenatal and postnatal study.

Authors:  S R F F Pedra; L K Hornberger; S M Leal; G P Taylor; J F Smallhorn
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

6.  Venous Doppler in the evaluation of fetal hydrops.

Authors:  C Hofstaetter; S Gudmundsson
Journal:  Obstet Gynecol Int       Date:  2010-05-05

Review 7.  Guidelines for the evaluation of heart failure in the fetus with or without hydrops.

Authors:  J C Huhta
Journal:  Pediatr Cardiol       Date:  2004 May-Jun       Impact factor: 1.655

Review 8.  Evaluation and Management of Fetal Cardiac Function and Heart Failure.

Authors:  Erik Michelfelder; Catherine Allen; Lindsay Urbinelli
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-09

9.  Clinical and echographic features of in utero cardiac dysfunction in the recipient twin in twin-twin transfusion syndrome.

Authors:  N Zosmer; R Bajoria; E Weiner; M Rigby; J Vaughan; N M Fisk
Journal:  Br Heart J       Date:  1994-07

10.  The aorto-left ventricular tunnel from a fetal perspective: Original case series and literature review.

Authors:  Amber E L van Nisselrooij; Anita J Moon-Grady; Annette Wacker-Gussmann; Viktor Tomek; Ivan Malčić; Agnieszka Grzyb; Anna Pavlova; Kalliopi Kazamia; Varsha Thakur; Elena Sinkovskaya; A Derk Jan Ten Harkel; Monique C Haak
Journal:  Prenat Diagn       Date:  2022-01-22       Impact factor: 3.242

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.